Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1/2 Open-Label Multicenter Study of Avadomide (CC-122) in Combination With R-CHOP-21 for Previously Untreated Poor Risk (IPI≥3) Diffuse Large B-Cell Lymphoma

Next Previous
X
Search
Trial Profile

A Phase 1/2 Open-Label Multicenter Study of Avadomide (CC-122) in Combination With R-CHOP-21 for Previously Untreated Poor Risk (IPI≥3) Diffuse Large B-Cell Lymphoma

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 25 Jul 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Avadomide (Primary) ; Cyclophosphamide; Doxorubicin; Pegfilgrastim; Prednisone; Prednisone; Rituximab; Vincristine
  • Indications Diffuse large B cell lymphoma
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Celgene Corporation

    • Most Recent Events

    • 28 Apr 2021 Status changed from active, no longer recruiting to completed.
    • 21 Jun 2020 Results analysing the safety and efficacy of avadomide plus R-CHOP in previously untreated patients with high-risk DLBCL presented at the 25th Congress of the European Haematology Association
    • 31 May 2020 Results (n=35; as 30 July 2019) of phase 1 part of the study evaluating efficacy and safety presented at the 56th Annual Meeting of the American Society of Clinical Oncology

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top